The partners will use UNP's AI-based macrocycle discovery platform to develop synthetic peptide therapeutics for multiple ...

Spokane may be hundreds of miles from major academic medical centers, but its becoming a national leader in an advanced ...

Cancer-hunting antibodies coupled with a natural compound found in soil microbes proved a powerful combination against an aggressive type of blood cancer, according to a new study from scientists at ...

Lynozyflic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

AKTIS ONCOLOGY INITIATES PHASE 1B CLINICAL TRIAL OF ITS NECTIN-4-TARGETING RADIOPHARMACEUTICAL PRODUCT CANDIDATE, AKY-1189, ACROSS MULTIPLE TUMOR TYPES By Aktis Oncology May 28, 2025 Updated 51 ...

AKTIS ONCOLOGY INITIATES PHASE 1B CLINICAL TRIAL OF ITS NECTIN-4-TARGETING RADIOPHARMACEUTICAL PRODUCT CANDIDATE, AKY-1189, ACROSS MULTIPLE TUMOR TYPES Provided by PR Newswire May 28, 2025, 4:00:00 AM ...

BOISE, Idaho — Plans are underway for a "Hetero Awesome Fest" on June 20-21, 2025, in Cecil D. Andrus Park, located directly in front of Idaho's Capitol building in Boise. The event, organized ...

Research published in the journal ESMO Real World Data and Digital Oncology, found that clinical research teams using Flatiron Clinical Pipe™ were able to accurately transfer thousands of data ...